A venture firm set up as an affiliate of Taipei-listed motor company Yulon Group is among the prior backers of Epitomics.
Aim-listed pharmaceutical company Abcam bought US-based antibodies company Epitomics International for $170m on Monday.
The acquisition price included $15m of cash on Epitomic’s balance sheet. The remaining $155m was paid half in Abcam shares and half in cash.
Epitomics has said on its website its shareholders included Chiron Corporation co-founder William Rutter, as well as venture firms Sycamore Ventures, Kenson Ventures, Amkey Ventures, and Brilliant Capital.
The company said in 2010 it had spun off portfolio company to shareholders…
